News in brief: NICE approves natalizumab for severe MS

The MS Trust has welcomed the decision by NICE to allow the use of Tysabri (natalizumab) for the treatment of rapidly evolving severe relapsing remitting multiple sclerosis (REMS). REMS is defined by two or more disabling relapses in one year with evidence of increasing lesions on two consecutive MRI scans. Tysabri is a powerful immuno-modular, which has shown impressive results in the treatment of MS. It was given a licence in June 2006 by the European Medicines Agency and is to be used as a single therapy.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus